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Assessing the bioavailability of drug molecules at the site of action provides better insight into the 
efficiency of a dosage form. However, determining drug concentration in the skin layers following 
topical application of dermatological formulations is a great challenge. The protocols followed in oral 
formulations could not be applied for topical dosage forms. The regulatory agencies are considering several 
possible approaches such as tape stripping, microdialysis etc. On the other hand, the skin bioavailability 
assessment of xenobiotics is equally important for topical formulations in order to evaluate the toxicity. 
It is always possible that drug molecules applied on the skin surface may transport thorough the skin 
and reaches systemic circulation. Thus the real time measurement of molecules in the skin layer has 
become obligatory. In the last two decades, quite a few investigations have been carried out to assess 
the skin bioavailability and toxicity of topical/dermatological products. This review provides current 
understanding on the basics of dermatokinetics, drug depot formation, skin metabolism and clearance 
of drug molecules from the skin layers following application of topical formulations.
Uniterms: Dermatological formulations/pharmacokinetics. Dermatological formulations/ toxicity. 
Dermatokinetics. Skin/metabolism. Microdialysis. Tape stripping. 
A avaliação da biodisponibilidade de moléculas de fármacos no sítio de ação oferece melhor compreensão 
sobre a eficiência da forma de dosagem. Entretanto, a determinação da concentração de fármaco nas 
camadas da pele em seguida à aplicação tópica de formulações dermatológicas é um grande desafio. Os 
protocolos seguidos para as formulações orais não podem ser aplicados para as formulações tópicas. 
As agências regulatórias consideram várias abordagens possíveis, tape stripping, microdiálise etc. Por 
outro lado, a avaliação da biodisponibilidade de xenobióticos na pele é igualmente importante para 
as formulações tópicas para se avaliar a toxicidade. É sempre possível que as moléculas de fármaco 
aplicadas na superfície da pele sejam transportadas através da pele e alcancem a circulação sistêmica. 
Assim, a medida em tempo real de moléculas na camada da pele tem se tornado obrigatória. Nas últimas 
duas décadas, realizaram-se poucas pesquisas para avaliar a biodisponibilidade da pele e a toxicidade de 
produtos tópicos/dermatológicos. Esta revisão fornece a compreensão atual com base na dermatocinética, 
formação de fármaco de depósito, metabolismo da pele e o clearance das moléculas de fármaco das 
camadas da pele em seguida à aplicação de formulações tópicas.
Unitermos: Formulações dermatológicas/farmacocinética. Formulações dermatológicas/toxicidade. 
Dermatocinética Pele/metabolismo. Microdiálise. Tape stripping. 
INTRODUCTION
Topical dermatological formulations are primarily 
intended to deliver therapeutically effective concentration 
of drug in skin layers, which are also the target site. 
Indeed, treatment of superficial skin diseases such as 
fungal infections could be accomplished with topical 
formulations. Many dermatological formulations are 
available and are specifically designed to exert local effect 
in the diseased skin, rather than diffusing into the deeper 
layers of skin. Primarily these formulations are aimed to 
deliver a therapeutically effective drug concentration in 
the target tissue, to exert a local effect, following topical 
application. However, the presence of several excipients 
which are potential to solubilise the outer skin layers 
allows the entry of drug moieties in the deeper skin layers 
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and even into systemic circulation. Novel vesicular 
formulations such as micro-emulsions, liposomes, and 
nanoparticles have demonstrated the potential to enhance 
cutaneous drug delivery of both lipophilic and hydrophilic 
drugs (Riviere, Brooks, 2011). It is understood that the 
properties of both formulation and drug are equally 
important in deciding the disposition of drug in the skin 
layers. Hence, it is likely that the individual drug molecule 
and excipient could exhibit different permeability 
behaviour (Desai et al., 2010). In addition, the presence 
of enzymes in skin causes variation of the structure of 
molecules and alters topical bioavailability. Hence, the 
in vivo activity of dermatological formulation depends 
on bioavailability of drug within the skin at the site of 
action (Bronaugh et al., 1994). In this context, researchers 
in the last few decades have given much emphasis on 
the assessment of skin kinetics of topical formulation. 
Following application of a topical drug formulation to 
the skin surface, it is likely that few processes occurs in 
a sequence such as release of drug from the dosage form, 
permeation of the drug into the skin barrier and exhibits 
the therapeutic responses such as onset of action, duration 
and magnitude of action.
The traditional methods for assessing the kinetics 
in blood, plasma or urine may not be viable as most of the 
topically applied molecules may not produce measurable 
concentrations in extra cutaneous biological fluids. It 
should also be remember that in topical therapy the drug 
concentration in the skin can significantly exceed free 
concentrations in plasma as the topical formulations 
deliver the drug directly to or near the intended site 
of action. Hence, determining drug absorption and 
elimination from the stratum corneum (SC) could be 
more promising. Thus, an ideal method to assess the skin 
kinetics would be a technique which allows non-invasive 
determination of rate and extent of drug within the skin. 
On the other hand, assessment of the rate and extent to 
which an active molecule attains its site of action in the 
target area (skin layers) is not considered as an easy task, 
due to the non availability of a simple and precise method 
for sampling the drug molecules from this region.
Bioavailability assessment of topical formulations 
remains a great challenge. Regulatory agencies like US 
Food and Drug Administration (FDA) have been exploring 
different strategies for the bioequivalence assessment of 
topical dermatological formulations. One of the methods 
suggested by FDA is the dermatopharmacokinetic (DPK) 
approach, wherein the drug concentration in the skin is 
determined continuously or intermittently for a period 
of time. Alternatively, microdialysis technique has been 
introduced to dermatological research as a valuable in 
vivo tool to assess the skin kinetics of topical formulations 
(Anderson et al., 1991; Kreilgaard, 2001). Further, several 
in vivo approaches have been also assessed to measure the 
topical bioavailability. This article provides a valuable 
insight into the basic considerations in the dermatokinetics 
of topical formulations.
SKIN BARRIERS
Skin is the largest organ of human body, which 
also act as a boundary between body and environment. It 
protects the body from chemical, physical, and microbial 
injury, loss of water, and other endogenous substances 
(Waugh, Grant, 2004). Skin covering an area of about 
2 m2 in an average human adult. It receives approximately 
1/3 of all blood circulating through the body. Skin with 
a thickness of few millimetres separates the underlying 
blood circulation network from outside environment. 
Anatomically, the skin has three major tissue layers: the 
epidermis, dermis and hypodermis (Jain, 2001). Epidermis 
is the outermost layer of skin and comprises of stratified 
keratinised squamous epithelium varies in thickness 
in different regions of body (Aulton, 2007). Epidermis 
consists of different layers such as SC, stratum lucidum, 
stratum granulosum, stratum spinosum and stratum 
germinativum. The barrier function of skin is strongly 
attributed to the SC. It consisted of 15-20 layers of acutely 
flattened, metabolically inactive, polygonal cells having 
a dry weight density of 1.3-1.4 g/cm3. Epidermis has no 
blood vessels or nerve endings, but its deeper layers are 
bathed in the interstitial fluid from dermis, which provides 
oxygen and nutrients and is drained away as lymph 
(Waugh, Grant, 2004). Dermis is tough and elastic, about 
3-5 mm thick, essentially consists of 80% of protein and 
matrix of connective tissue woven from fibrous proteins 
(Jain, 2001; Aulton, 2007). Collagen fibres bind water and 
give the skin its tensile strength (Waugh, Grant, 2004). 
Branches from the arterial plexus supply blood to sweat 
glands, subcutaneous fat, hair follicles and dermis. Sweat 
glands are found all over the skin and most numbers in 
palms of soles of the feet, palms of the hand, axillae and 
groins. However, hair follicles are found all over the skin 
surface except soles of the feet, palms of the hand and red 
part of the skin (Aulton, 2007).
DRUG ABSORPTION IN SKIN
Absorption of drug or chemicals into the skin is 
influenced by several factors. These include molecular size, 
lipophilicity, pH of formulation, penetrant concentration, 
chemical enhancers, skin hydration, skin enzymes, 
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temperature, formulation compositions etc and are 
discussed briefly.
Percutaneous absorption is inversely proportional 
to molecular weight, which particularly affects the 
diffusion coefficient. Molecules of size larger than 500 
Daltons usually have more difficulty to penetrate through 
the SC (Bos, Meinradi, 2000). For optimal permeability 
lipid/ water partition coefficient is expected to be 1 or 
greater. Further, release of drug on to the skin surface is 
highly influenced by its partition coefficient and pH of 
vehicle. Application of formulation with a high or very 
low pH values can harm the skin. Hence a moderate 
pH values [typically above the isoelectric point (pI~4) 
of skin] could be more appropriate for topical delivery 
(Merino et al., 1999). However, degree of drug ionization 
at particular pH is of great importance, as unionized 
molecules predominantly diffuse through the lipophilic 
intercellular regions of the SC. On the other hand, the skin 
is negatively charged at physiological pH and therefore is 
cation-permselective (Marro et al., 2001). Furthermore, 
ionized drug molecules may also permeate through the 
intercellular regions of the SC, but in a slow and low 
mode. Moreover, ionized drug molecules forms pair with 
ion present in the skin, leads to neutral compounds which 
are competent of crossing the skin barrier (Govil, Tayle, 
1998; Mishra, Jain, 2002; Mbah et al., 2011).
The concentration of drug in the formulation is 
equally important. A proportional increase in flux can 
be obtained by increasing the concentration of dissolved 
drug. At higher concentration above the solubility, the 
excess solid drug acts as a reservoir (often causes drug 
crystallization in patches) and maintain constant drug 
level for a prolonged time (Govil, Tayle, 1998; Mishra, 
Jain, 2002; Mbah et al., 2011). Further, the presence of any 
chemical permeation enhancers will augment the delivery 
of drugs into the skin layers. In addition, skin occlusion 
with impermeable plastic films or wraps prevents the 
water loss from the skin surface. This increases the level of 
hydration in the SC which in turn decreases the diffusional 
path length and protein network density, favouring 
the drug transport. The rate of occlusion decreases in 
following order: occlusive film = transdermal patches > 
lipophilic ointments > w/o cream > o/w cream. For a large 
temperature variation (10-37 oC), the penetration rate of 
material through skin change ~10 folds, since diffusion 
coefficient decreases as temperature falls (Jetzer et al., 
1988). Occlusive vehicles are likely to increase the skin 
temperature by 2-30C resulting in increased molecular 
motion and permeability (Hotchkiss et al., 1992). 
Moreover, skin metabolizes chemical carcinogens, steroid 
hormones and certain topical drugs. Thus the therapeutic 
efficacy of topically applied compounds particularly 
prodrugs and carcinogenic responses in the skin may 
be determined by such metabolism (Aulton, 2007). Last 
but not least, the formulation compositions including the 
polymer are likely to influence both the drug release rate 
and the SC permeability (Kandavilli et al., 2002).
Assessment of dermatokinetics
Assessment of the skin kinetics of topical 
formulations is likely to provide the drug bioavailability 
of the applied formulation, which in turn results in the 
effective treatment of dermatological diseases. However, 
the definition of bioavailability for systemically acting 
drugs could not be extended to topical drugs. No correlation 
exists between the availability of drug in the skin and with 
the resulting blood levels. Hence the evaluation of topical 
bioavailability must involve the quantification of drug in 
target tissue itself. Indeed, most of the topical formulations 
are intended to act on the upper skin layers, rather than 
diffusing into and through the epidermis. For instance, 
the treatment of fungal infection of skin (wherein the 
fungi reside in the SC) and a direct measurement of drug 
at the site of action (SC) is likely to provide better insight 
in to the pharmacokinetics. However, in some instances, 
the target site for topical formulation may not be the SC 
although it will pass through this barrier, except when the 
SC is compromised (damaged/diseased condition). Hence 
the assessment of drug concentration in the SC should be 
generally applicable to all topical dermatological drug 
formulations including antifungal, antiviral, antiacne, 
antibiotic and corticosteroids. 
The skin kinetics study is comparable to a typical 
blood, plasma, urine pharmacokinetic study. However, it 
must be borne in mind that the pharmacokinetic parameters 
in skin are not only dependent on the absorption (in the 
case of oral administration) but also depends on the time 
at which drug administration is stopped by removal of 
any remaining formulation on the skin surface. Further, 
the percutaneous absorption is a low and slow process and 
always there is possibility that the applied formulation will 
be removed before the absorption phase is completed. In 
general, the evaluation of DPK involves the assessment 
of the drug concentration in the outer most layers of the 
skin (SC) with respect to time and provides information on 
drug absorption, steady state and drug elimination based 
on a SC concentration-time curve (Guidance for Industry, 
1998). Moreover, one of the in vitro- in vivo correlations 
for topical preparations can be obtained by measuring the 
drug release from formulation and in vivo measurement of 
drug concentration in the SC or DPK (Shah, 2005).
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Parameters such as maximum quantity of active 
drug molecules in the SC (Cmax), time to reach maximum 
level (Tmax), and area under the curve of drug level in 
the SC versus time (AUC) are proposed as metrics for 
assessing bioequivalence of topical drugs (Shah, 1998). 
Following the topical application, drug levels in the SC is 
assessed as a function of time of post application and post 
removal of the formulation, to generate SC concentration 
versus time profile. The DPK method assumes that: (a) 
SC is the rate-limiting barrier to percutaneous absorption, 
(b) drug concentration in the SC is directly related to 
drug’s diffusion into the viable dermis and (c) SC drug 
concentrations are more relevant for estimating local, 
dermatological efficacy than plasma concentrations (Nicoli 
et al., 2009). It has also been possible to deduce drug’s 
partitioning and diffusion parameters which characterize 
the absorption process and which can subsequently be used 
to predict an entire absorption profile from a single short 
contact duration experiment (Shah, 1998).
APPROACHES IN DERMATOKINETCIS 
STUDIES
Frequent measurement of drug levels in the skin is 
essential to provide a good estimate of the drug amount in 
the skin as a function of time and to derive dermatokinetic 
parameters (Cmax, Tmax and AUC) of a definite value. Hence 
the FDA draft guidance for DPK specifies that drug levels 
should be assessed at least eight different sites: at four of the 
sites levels are measured during uptake (e.g. 0.25, 0.5, 1, and 
3 h post-application), then, after cleaning the drug from the 
remaining sites, levels are assessed during clearance (e.g. 
4, 6, 8, and 24 h post application) (Guidance for Industry, 
1998). However, it is likely that the amount of drug in 
samples measured after longer clearance times will be less 
than the limit of quantification or the limit of detection, 
which eventually leads to the incomplete or erratic data. 
Further it is also recommended to collect all the skin 
samples on a single day, in order to avoid inter day variation, 
which is of much concern due to the limited skin availability 
in a given subject. Moreover, the success of the skin 
kinetic study is equally dependent on the development of 
sensitive analytical methods to quantify the amount of drug. 
Certain invasive techniques such as indirect radiochemical 
methods, surface scrapping, sampling of hairs, suction 
blister sampling and biopsies, which are too non-specific 
or too traumatic, are not preferred for routine use in human 
and have not been discussed in this article. However, few 
feasible methods for the pharmacokinetic assessment of 
topically formulations such as tape stripping, microdialysis 
and vasoconstrictor assay are discussed below.
Tape stripping technique
Tape stripping is applied in various areas of 
cutaneous biology such as determination of the barrier 
function, inspect dermato-pathologies, examine gene 
expression, check pH profiles, inspect animal skin as 
a surrogate for human skin (Herkenne et al., 2008). 
Moreover, it presents an alternative for local bioavailability 
or bioequivalence assessment of topically applied drugs 
whose target is the underlying viable tissues (Lademann 
et al., 2009). This technique in its standardized form is 
well suited to determine the DPK of topical formulations, 
where the drug concentration is determined in the SC 
layers, which are progressively removed by tape stripping. 
This method is a simple, efficient, quick and relatively 
non-invasive approach to assess the quality and efficacy 
of drugs, excipients, cosmetics in the skin following the 
topical dermatological application (Escobar-Chávez et al., 
2008). Indeed, the drug or excipients level in the skin can 
be determined either in the removed tape strips, or directly 
in the tape stripped skin. Typically, after topical application 
and penetration of formulations, the cell layers of SC are 
collected by the successive application and removal of 
adhesive tape (Figure 1). Then the drug concentration on 
each tape is determined individually, penetration profiles 
may be derived, as a function of depth within the SC 
(Russell, Guy, 2009). The data thus obtained could be used 
for comparison of the penetration of different formulations 
to assess the bioequivalence. The FDA draft guidance 
indicates the assessment of both drug uptake into and drug 
elimination from the SC by tape stripping technique. In 
addition, the method can be employed both in vivo and in 
vitro, and in humans and animals such as pigs, rats, guinea 
pigs and mice (Lademann et al., 2009).
Several precautions need to be taken while carrying 
out the tape stripping (Boix-Montanes, 2011; Lademann 
et al., 2009). The first one could be the site of application. 
In general, the site of application must be free of both 
terminal and vellus hairs and uneven areas, e.g., caused 
FIGURE 1 - Adhesive tape stripping of stratum corneum.
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by scars and underlying muscles. However, the hairy 
sites can be made useful after carefully removing the 
hair using scissors or special cutters but avoid shaving. 
Secondly, the choice of adhesive tape and its application 
for stripping the SC need to be optimized. One can use 
an adhesive tape directly or cutting it into definite size 
which possess uniform composition and distribution of 
the adhesive layer on the tape strip. However, attention 
should be made during application of adhesive tape strip to 
ensure complete adherence of tape on the marked skin area 
and avoid folding of tape. Further, application pressure 
should be constant in order to obtain a uniform removal 
of SC and to obtain a reproducible data. This can be 
achieved by using a constant weight or spatula or a roller, 
although the roller is preferred. In general, adhesive films 
are placed on the skin and applied a gentle force using a 
roller to stretch the skin surface and assure good contact 
(Nicoli et al., 2009). This in turn will avoid the influence 
of furrows and wrinkles under the tape stripping. Thirdly, 
velocity of stripping the tape; a constant velocity would 
be preferred which ensures removal of uniform amount of 
SC. Moreover, it must be kept in mind that the successive 
application and removal should be carried out from the 
same treated skin area. In addition, there are several factors 
which could eventually alter the quantity of SC removed 
in each adhesive tape strips. These include size of the 
corneocytes, number of cell layers, thickness of SC, age 
and composition and amount of lipids (depending on the 
anatomical site) (Lademann et al., 2009).
Several methods have been proposed to quantify 
the amount of SC removed by individual tape stripping. 
These include weighing, spectroscopic and microscopic 
measurements (Lademann et al., 2009). In the case of 
weighing method, weighing tapes before and after stripping 
has been used to estimate the mass of SC removed per tape. 
The mass is further converted to SC thickness using the 
area and SC density. The main limitation of this method 
is the process remains time consuming and laborious. 
However, the spectroscopic method will measure the 
amount of proteins in the corneocytes (component of SC) 
which has absorption at 278 nm, and can be estimated 
using a spectrophotometer. On the other hand, optical 
microscope could be used to take the images of the 
corneocytes adhered to a tape strip and relative covering 
density is determined. The estimation of transepidermal 
water loss (TEWL) before the first tape strip and after a 
set number of tape strips to determine the exact number 
of tapes required for the complete removal of SC. A 
point wherein the TEWL attains ~8 times higher than the 
baseline value is an indicator that the SC is completely 
tape stripped (Shah, 2001).
The amount of drug in the tape strips can be 
estimated by extracting the amount of absorbed drug. 
One can correlate this drug level with those attained in 
the underlying viable components of the skin (Incecayir, 
2011). In general, the first tape strip is discarded as it 
represents the drug on the skin surface (unabsorbed). 
However, the amount of SC removed by the first tape is 
highly influenced by the presence of furrows, formulation 
composition and the duration of study (Sheth et al., 1987).
The draft guidance by US Department of Health and 
Human Services in 1998 has proposed the determination 
of the drug level in the SC using tape stripping as a DPK 
approach to assess the bioequivalence (N’Dri-Stempfer et 
al., 2008). As mentioned before, the protocol specifies that 
each formulation should be applied to at least eight sites, 
divided equally for studying the kinetics (at four different 
times post-removal) of drug uptake and clearance. Each 
treatment is further tape stripped for 12 times, while the 
first two are discarded and the remaining is combined and 
quantified. It is also recommended that the performance 
of a topical formulation should be quantified in a similar 
manner which reflects the bioequivalence tests for oral 
drug bioavailability in which blood levels are measured 
(Guidance for Industry, 1998). The amount of drug 
determined in the tape strip samples should be represented 
as AUC, Cmax and Tmax (Figure 2), and a comparable data of 
two topical products would be considered bioequivalent. 
However, in 2002, the FDA partially withdrawn the DPK 
guidance due to doubts regarding the reproducibility of 
method and concern regarding the quantification of actives 
in the SC.
Microdialysis
Microdialysis, a minimally invasive technique, 
FIGURE 2 - Schematic diagram illustrating the DPK drug 
analysis in the stratum corneum by tape stripping methodology 
recommended in FDA guidance 1998.
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has been introduced to dermatological research as a 
valuable in vivo tool for the assessment of bioavailability 
and bioequivalence of topical formulations (Anderson 
et al., 1991; Kreilgaard, 2001). This technique has been 
successfully applied to assess cutaneous drug delivery 
of numerous endogenous and exogenous compounds 
in the extracellular spaces of tissues and for assessing 
pharmacokinetic and pharmacodynamic response (Shah, 
2001). Indeed this method is capable of measuring free 
drug concentrations at the site of drug action over time and 
thereby enables the assessment of local pharmacokinetic 
profile of topical drug penetration from each sampling 
site (Groth, 1996; Kreilgaard, 2001; Herkenne et al., 
2008). Currently, this method has been recognized by the 
industries and regulatory authorities for bioavailability 
and bioequivalence determination of topical dermatologic 
products. Microdialysis is also combined with a wide 
variety of non invasive methods developed to observe 
barrier function and functional status of the skin (Schnetz, 
Fartasch, 2001).
A microdialysis probe consists of a small , 
semipermeable hollow fiber membrane (~0.4 mm 
diameter) that is connected to inlet and outlet tubing. 
The probes are of linear or concentric. Depending on 
the probe design, the fibre has one end connected to an 
afferent impermeable tube, which leads to a micropump, 
and the other end to an efferent sampling tube. During 
microdialysis, the probe is implanted in the dermis of 
the skin via a guide cannula, parallel to the skin surface, 
with or without local anesthesia at the site of entry. The 
microdialysis fibre is then constantly perfused with a 
sterile physiological solution (perfusate) at flow rates of 
approximately 0.1 to 5 µL/min through a microdialysis 
pump. In the dermis, probe functions as an artificial 
vessel, while the perfusate equilibrates extracellular fluid 
of surrounding tissue, and exchange substances smaller 
than the cut-off value of membrane from probe to tissue 
and vice versa (Ault et al., 1994). The mechanism for 
transport of solutes across the membrane is by passive 
diffusion depending on their concentration gradient. 
Hence, compounds can be separated or can be added to 
extracellular space by diffusion through dialysis membrane 
(Shah, 2001). The solution leaving the probe (dialysate) 
is collected at certain time intervals for analysis. Samples 
obtained are protein free and easily analysed without any 
further analytical purification. However, sampling of very 
lipophilic and highly protein bound drugs can produce 
problems due to their low recoveries with this technique. 
Further, relatively large differences in individual drug 
levels were observed in between individuals and between 
microdialysis probes. The recovery of substances is highly 
influenced by drug clearance from tissues surrounding 
microdialysis membrane, diffusivity of substance, 
capillary blood flow around the probe and partition 
coefficient between perfusates and tissues. These factors 
are likely to alter during an experiment and between 
application sites (Kreilgaard, 2001; Wu et al., 2009).
Important parameter for the efficacy of microdialysis 
is the relative recovery of probe, which has to be 
determined before performing microdialysis. Due to 
steady flow of perfusate through the probe, equilibrium 
between the concentration of dialysate and substance in 
extracellular fluid will be reached immediately. However, 
the steady state concentration of substance of interest 
(Cdialysate) will not be same as in the extracellular fluid 
(Ctissue) and the ratio represents relative recovery, which can 
be calculated as Relative Recovery = {(Cdialysate - Cperfusate)/ 
(Ctissue - Cperfusate)} (Schnetz, Fartasch, 2001).
Microdialysis  technique has been applied 
successfully in human volunteers to study the cutaneous 
release of histamine in response to different topical stimuli 
and the penetration of a number of organic solvents 
(ethanol and isopropranol). This could be utilized in 
measuring inflammatory mediators in dermis, study skin 
metabolism, determine the drug absorption or other agents 
in skin and as an alternative route of drug administration 
(Kreilgaard, 2002). Currently microdialysis exercised 
in the field of clinical research for the monitoring of 
secondary ischemia in neurointensive care or glucose 
monitoring for long term metabolic control in patients with 
diabetes mellitus. It can give very detailed chronological 
pharmacokinetic data and simultaneously several sampling 
sites can be considered in the same volunteer.
Vasoconstrictor assay
Human skin blanching assay also known as 
vasoconstrictor assay is a well established method used 
to assess the safety and efficacy of topical products 
during clinical studies. This method is restricted to the 
bioequivalence assessment of topical corticosteroid 
formulat ions (Larsson,  1991).  Vasoconstr ictor 
assay method follows the FDA guidance for topical 
dermatological glucocorticoids - in vivo bioequivalence 
(Kanfer, 2010). A hill top chamber (~1.2 cm) is affixed to 
the skin surface with adhesive tape and specified volume 
of formulation or sample was applied in the chamber. 
Volar forearm regions are selected for drug application, 
at least 4 cm from the wrist and 4 cm from the antecubital 
fossa. Formulation is applied for a fixed duration and 
the chambers are removed and excess formulation is 
cleaned off, then skin blanching response is measured for 
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a prescribed period of time (Guidance for Industry, 1995). 
The visual assessment is based on the application of an 
intensity scale 0-4 where zero indicates no blanching and 
numbers 1-4 assigned to increase in degree of blanching 
observed. The blanching response can be assessed by 
one or more observers used are taken into consideration 
for data processing. The total possible score expressed in 
percentage and is determined as (Kanfer, 2010);
Total possible score = 5x4xSxV
Where V is the number of subjects, S is the number of 
sites/product/arm, 4 signify the number of independent 
assessors and 5 represents the maximum score/site.
Confocal laser scanning microscopy
Confocal laser scanning microscopy is another 
important tool for the assessment of DPK parameters. The 
confocal images are possible for fluorescent drugs or probes 
and do not required to prepare the skin to make optical 
sections. This tool focuses a beam to a given depth within 
the tissue and measures the concentration of penetrant or 
drug molecule at the level of focus. Thus, this tool allows 
an investigator to generate a concentration profile following 
topical application of drug product (Grasso, Lansdown, 
1972; Mayee, Rawat, 2010). The confocal images can 
be obtained in the plane parallel to sample surface or in 
the plane perpendicular (Wu et al., 2009). This method 
has been widely used in assessing drug penetration or 
distribution in the skin layers following topical application 
of microparticles, nanoparticles and vesicular systems such 
as liposomes, niosomes etc (Desai et al., 2013; Khurana et 
al., 2013; Verma et al., 2013; Wang et al., 2013).
SKIN DRUG CLEARANCE
The majority of dermatokinetic studies have 
focused on the absorption phase of DPK. However, the 
fate of the molecule after the absorption has not studied 
much, although is equally important in assessing the 
bioavailability of the topical formulations. It is likely that 
the drugs with distinct characters are likely to transport 
into the dermis and therein to the systemic circulation by 
entering lymphatic or blood vessels in the dermis (Murthy 
et al., 2010). Following skin permeation, the key process 
involved is clearance (Wiedersberg et al., 2009). The 
disposition of topically applied drug could be influenced 
by physicochemical properties and the manner in which 
the active species is presented to the skin; that is, the 
formulation.
The pharmacological effects of topical drugs or 
substances are directly dependant on microvascular 
parameters such as blood flow rate. The microenvironment 
inside the skin is a vibrant part of the body which alters 
constantly (Krestos, Kasting, 2005). The skin possesses 
a rich vascular network system which regulates and 
deals various activities in the skin (Krestos et al., 2004). 
Cutaneous microvasculature is enclosed in the papillary 
dermis (1-2 mm below the epidermal surface) and consists 
of two horizontal plexus (Haake, Holbrook, 1999; Cevc, 
Vierl, 2007). The lower one is located near the dermal-
hypodermal junction that gives rise to arterioles and 
venules. The second plexus located approximately 1-2 mm 
below the skin surface represent the boundary between the 
papillary and reticular dermis (Braverman et al., 1990). 
Three types of capillaries are found in the human body- 
continuous, fenestrated and discontinuous. Continuous 
capillaries are located in the skin and skeletal muscle, and 
are least permeable. The dermal capillary may be assumed 
as a bent, capital lambda shaped cylinder with its ventral 
part being broader internally and externally. The capillaries 
are most important in relation to the clearance because it 
is the first permeable parts of circulation encountered by 
a topically applied permeant (Braverman, 1997). Usually, 
there is one capillary per papilla and their surface density 
is approximately 50 or 60-70 capillaries per mm2 of the 
skin surface (Wiedersberg, 2009).
Lymphatic clearance route has extremely high 
permeability which becomes important for macromolecules 
which are not able to cross the microvascular barrier due 
to their size. The lymphatic system has the function to 
take away debris of daily wear and tear in a tissue. In the 
human skin, lymphatics first appear at the subpapillary 
dermis (Wiedersberg, 2009). Initial lymphatic vessels are 
cylindrical microtubules approximately 50 µm in diameter 
and are consists of weakened endothelial cells (Krestos 
et al., 2007). On the average, lymphatic channels have 
the number density of 0.3-1.5 µm2 (Wiedersberg, 2009). 
Large molecules such as proteins, large sugars are cleared 
entirely by lymph vessels when injected intradermally. The 
removal of these molecules gives an evidence of lymphatic 
utility of the skin (Spiegel et al., 1992). The transport 
of drug molecules is primarily by passive transport and 
pressure gradients across the blood tissue barrier. Several 
routes have been classified in the capillary wall structure 
as pathways available for exchange. Depending on the 
solutes size, nature and lipophilicity, they may prefer one 
or more of these pathways (Leu, 2001). Interendothelial 
cell junctions are the preferred pathway for the transport 
of hydrophilic solutes and also important for the small 
lipophilic solutes. They resemble the pores or slits filled 
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with extracellular phase. Secondly, the endothelial cells 
allows the transport of lipophilic solutes, water etc 
(Michel, Curry, 1999). Dermal/ cutaneous clearance is 
highly related to physiology of the blood vessels and 
physicochemical properties of drug moieties. Parameters 
such as the thickness of blood vessel, area, distance 
between blood vessels and blood flow rate likely to alter 
the drug clearance.
SKIN METABOLISM
Skin contains all the major enzymes which are 
found in the liver and other tissues and are capable of 
catalysing a number of metabolic reactions. Metabolism 
of the topically applied compounds result in altered 
pharmacological and toxicological effects (Reed, Rubin, 
2010). However, the activity of enzymes in skin has 
found to be less as compared to liver. Hence, the skin 
can act as a gateway for the entry of drug molecules into 
the body (Bronaugh, Maibach, 2002). There are number 
of chemical groups which are particularly susceptible to 
skin metabolism such as alcohols, acids, primary amines, 
esters etc. The viable dermis comprises of different 
drug metabolising enzyme include epoxide hydrolase, 
CYPs, transferases (N-acetyl transferases) glucuronyl 
transferases and sulfatases. Further, the metabolism of 
retinoic acid by a specific CYP isoform, CYP26A1 and 
the human keratinocytes contains transporter proteins 
which influence influx or efflux of some xenobiotics 
were reported (Bronaugh, Maibach, 2002). There are 
reports indicating the conjugation and oxidation/reduction 
of alcohols and acids by the skin enzymes. The drug 
molecules or chemical substances may exhibit greater or 
lesser biological activity that undergoes significant skin 
metabolism than predicted simply from skin penetration 
studies. The in vivo measurement of skin metabolism 
is difficult task because biological specimens may also 
contain metabolites from other tissues (Bronaugh et al., 
1994). However, the skin metabolism can be evaluated by 
conducting in vitro permeation studies using viable skin 
or the metabolites can be measured in skin homogenate 
or in the receptor fluid (Bronaugh, 1995).
DRUG DEPOT IN SKIN
The formation of drug depot in the epidermal region 
of the skin following topical application has been reported 
in several scientific publications. In general, drug reservoir 
in the skin layers is likely to release over an extended period 
of time (Zhai, Maibach, 2004; Nair et al., 2011; Nair et 
al., 2012). Recently, the application of iontophoresis to 
create depot of acyclovir was reported which would be 
beneficial for the effective treatment of viral infections by 
providing sustained release of drug over an extended period 
(Anderson et al., 2003). Several investigations has reported 
the prospective of vesicular carrier systems to facilitate 
localization of drug at the application site by forming 
depot and reduce the frequency of application, decreases 
the dose and systemic side effects when compared to 
conventional topical therapies (Siddoju et al., 2011). Silver 
nanoparticles, quantum dots, functionalized fullerene etc 
have been used to investigate and substantiate the possible 
drug depot following the topical application (Murthy et al., 
2011). Numerous reports have shown localization of nano 
systems at the SC layer and follicular regions (Lademann 
et al., 1997; Schulz et al., 2002; Lademann et al., 2007; 
Zvyagin et al., 2008). Quantum dots of different sizes have 
been used to study the penetrability of nanoparticles across 
the layers of skin. Vogt et al have showed that particles of 
40 nm size have penetrated through the depth of 225 µm 
or in the region of epidermis or papillary dermis (Vogt et 
al., 2006). Kohli and Alpar (2004) have shown that the 
penetrability of nanoparticles across the skin depends 
not only on the size but also on the charge present on the 
surface of the particles. In general, most of the studies have 
demonstrated the penetrability of nanoparticles in the size 
range of <40 nm regardless of the surface charge across 
the SC via follicular as well as intercellular pathways. It is 
likely that the particles in this size range would be able to 
penetrate better if the intactness of the upper most layer, SC 
is compromised. In one attempt, titanium dioxide particle 
were exposed for 2-6 weeks in the epidermis and dermis of 
patients to determine amount of titanium in skin layers. The 
data indicate that there was no drug depot in the skin layers, 
although the exact reason is unidentified. On the other hand, 
lipid microparticles with > 1 µm are able to retain on the 
skin surface or localized on the hair follicles surfaces and 
form a film layer on the skin surface which can be helpful 
in sunscreen formulations for the protection against UV 
radiation (Devi et al., 2011). The residence time in different 
skin layers can be determined by the tape stripping and skin 
extraction studies at various time intervals following drug 
application. In addition, topical drug deposition can be 
assessed quantitatively by tape stripping method and could 
be extended in determining the follicular deposition when 
it is used in combination with visualization by microscopic 
methods (Reed, Rubin, 2010).
CONCLUSION
Assessment of  dermatokinet ics  of  topical 
dermatological formulations is utmost important 
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in assessing the safety and efficacy of the products. 
Numerous approaches are reported and being used to 
determine the real time measurement of molecules in 
the skin layers. Regulatory agencies like U.S. FDA are 
still exploring different techniques to characterize drug’s 
dermatopharmacokinetics. Parameters such as maximum 
quantity of drug active molecule in the SC (Cmax), time 
to reach maximum level (Tmax), and area under the 
curve (AUC) are widely assessed in dermatokinetics 
studies. Different methods are reported for assessing 
pharmacokinetic profile of topically applied drug 
molecules which includes tape stripping, microdialysis, 
vasoconstrictor assay, confocal laser scanning etc. Certain 
dermatological product applied on the skin surface is 
likely to permeate into the deeper tissue layers and reach 
systemic circulation. Further, most of the molecules enters 
into the dermis are quickly cleared by the microvascular 
system, although few molecules retain in the skin and 
produce depot effect.
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